FDA Approval of Semaglutide for MASH Marks a Turning Point in Liver Care A Global Burden: MASLD and MASH Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD, affects roughly 30% of adults worldwide
Medical weight loss involving Semaglutide and Tirzepatide is a clinically supervised approach to losing weight and managing obesity
External resources SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide (New England Journal of Medicine) SYNERGY-NASH Trial Results (American College of Gastroenterology) SURMOUNT-OSA: Tirzepatide for Sleep Apnea and Obesity (PubMed Central) In case I do not see you, good afternoon, good evening, and good night
They help control appetite, reduce cravings, and improve metabolic function
Novo Nordisk's blockbuster obesity treatment Wegovy mimics a hormone called GLP-1 to tamp down appetite and regulate blood sugar, while Eli Lilly's own drug Zepbound targets both GLP-1 and another hormone called GIP